DarioHealth Corp. (NASDAQ:DRIO) is a leading global Digital Therapeutics (DTx) Company, revolutionizing the way people manage their health across the chronic condition spectrum.

By delivering evidence-based interventions that are driven by data, high quality software and coaching, we have developed a novel approach that empowers individuals to adjust their lifestyle in a personalized way.

Our Cross Functional Team operates at the intersection of biology, behavioral science, and software technology to deliver highly engaging therapeutic interventions.  Already the highest rated diabetes solution by more than tens of thousands of consumers who love our user-centered approach, DarioHealth is rapidly moving into new chronic conditions and geographic markets.

Founded in 2011, DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed unique ways for people to analyze and personalize their chronic disease management. DarioHealth’s approach has taken the best of both worlds – the world of the wearable market, which is projected to reach $51.6B in just a few years, and the monitoring market that is climbing toward the $30B mark – and flipped traditional health upside down. We are moving from periodic data to continuous data, from general treatment to personalized treatment, and from theory-driven solutions to adapted data & AI/ML technology. DarioHealth’s solutions span the full spectrum of disease monitoring, management, populations, and engagement.

What truly makes DarioHealth remarkable is the fact that it has steadily grown from being a user-centric, direct-to-consumer company to a mature organization that is fully data-driven and able to provide a wide-range of managed care solutions. At the hub of it all is DarioHealth’s proprietary engagement platform, which has been painstakingly built by carefully monitoring and analyzing big data. Today, DarioHealth boasts phenomenal solutions and automated, full-suite services for the biggest players in the diabetes care management space.

The company is led by visionary CEO, Erez Raphael. After years in software development and senior management roles at some of Israel’s leading high-tech companies, Mr. Raphael had a close encounter with diabetes and decided to channel all of his energies into combatting this disease that affects a fast growing number of people each year. Under his leadership, the company was uplisted to the Nasdaq market under the ticker name DRIO.

The world leading Dario Blood Glucose Monitoring System has US FDA clearance and approval from the European CE, Health Canada, and Australia’s TGA. It is commercially available in the United States, Canada, the United Kingdom, Germany, Italy, and Australia.

Our team

Erez Raphael

Chief Visionary & CEO

Zvi Ben-David


Dror Bacher


Olivier Jarry

President, CCO

Tracey Wielinski

Acting VP RA/QA/CL

João Mendes-Roter

VP Marketing

JC Muyl

Head of Commercialization - North America

Dominique Wilkins

Legendary Customer

Yinon Amir

Head of Software Innovation

Alon Yefet

Customer Relations Manager

Eitan Feinger

Director, R&D

Jacob Shafir

Customer Success Manager

Dov Oppenheim

Co-Founder & Production Chief

Nir Ziv

Director of Operations

Professor Itamar Raz

Medical Director

Eti Visbrot

Talent Manager

Yahel Nir

Director of Finance

Lyr Bar

Director of Quality

Ran Shochat

Software Development Director

Inbal Gross

Design Experience Manager

Yifat Hershcovitz, Ph.D

Scientific Manager

Susan Sloane, RPh, CDE

Scientific Advisory

Janice Baker, RD, CDE, CNSC, BC-ADM

Scientific Advisory

Sara Kahn, RN

Sales Team Leader

Board of Directors

Yoav Shaked


Erez Raphael

Allen Kamer

Dennis M. McGrath

Professor Richard Stone

Hila Karah

Colonel (IDF res.) Yalon Farhi

Glen Moller

Advisory Board

Robert G. Faissal

Erez Levy

Dr. Peter Kash